Regulis has strengthened and expanded its regulatory team with the recent appointments of Navjeet Jolly and Silvia Stingele.
In her past roles, Navjeet has managed global registration projects, working previously on both pharmaceuticals and devices particularly in international markets. Silvia has previous experience from a CRO environment, working in both clinical trial and regulatory affairs roles. The latter role included writing and gap analysis of IMPDs, EMA scientific advice procedures, EU orphan drug applications, preparation and submission of variations and clinical trial amendments. Kim Wharton said Navjeet and Silvia were the standout candidates from a rigorous interview process and will be vital members of our expanding regulatory team.